AUTOLIV, INC. financials
AUTOLIV, INC.
Country: SE Reporting currency: USD Latest annual report: 2024-12-31
LEI:
A23RUXWKASG834LTMK28 Financial statements
(USD, as reported — unscaled; 102 line items across 3 annual periods)
| Line item | 2024 | 2023 | 2022 |
|---|---|---|---|
| Income statement | |||
| Revenue | $10.39B | $10.47B | $8.84B |
| Cost of sales | $8.46B | $8.65B | $7.45B |
| Gross profit | $1.93B | $1.82B | $1.40B |
| Operating profit (EBIT) | $979.0M | $690.0M | $659.0M |
| Profit before tax | $875.0M | $612.0M | $603.0M |
| Income tax expense | $227.0M | $123.0M | $178.0M |
| Profit for the year | $648.0M | $489.0M | $425.0M |
| — attributable to owners | $646.0M | $488.0M | $423.0M |
| — attributable to NCI | $1.0M | $1.0M | $2.0M |
| Total comprehensive income | $484.0M | $514.0M | $309.0M |
| Per share | |||
| Basic EPS | $8.06 | $5.74 | $4.86 |
| Diluted EPS | $8.04 | $5.72 | $4.85 |
| Free cash flow / share | $5.97 | $4.80 | $1.47 |
| Cash flow statement | |||
| Net cash from operating activities | $1.06B | $982.0M | $713.0M |
| Net cash from investing activities | -$563.0M | -$569.0M | -$485.0M |
| Purchase of PP&E (capex) | $579.0M | $573.0M | $585.0M |
| Net cash from financing activities | -$680.0M | -$490.0M | -$531.0M |
| Balance sheet | |||
| Total assets | $7.80B | $8.33B | — |
| Non-current assets | $4.32B | $4.36B | — |
| Property, plant & equipment | $2.24B | $2.19B | — |
| Right-of-use assets | $158.0M | $176.0M | — |
| Intangible assets & goodwill | $1.38B | $1.39B | — |
| Current assets | $3.48B | $3.97B | — |
| Inventories | $921.0M | $1.01B | — |
| Trade & other receivables | $1.99B | $2.20B | — |
| Cash & equivalents | $330.0M | $498.0M | $594.0M |
| Total equity | $2.29B | $2.57B | $2.63B |
| — attributable to owners | $2.28B | $2.56B | — |
| Non-controlling interests | $10.0M | $13.0M | — |
| Non-current liabilities | $1.89B | $1.73B | — |
| Long-term borrowings | $1.52B | $1.32B | — |
| Lease liabilities (non-current) | $118.0M | $135.0M | — |
| Current liabilities | $3.63B | $4.04B | — |
| Short-term borrowings | $387.0M | $538.0M | — |
| Lease liabilities (current) | $41.0M | $39.0M | — |
| Trade & other payables | $1.80B | $1.98B | — |
| Derived metrics | |||
| Free cash flow | $480.0M | $409.0M | $128.0M |
| Operating margin | 9.4% | 6.6% | 7.5% |
| Net margin | 6.2% | 4.7% | 4.8% |
| Return on equity | 28.4% | 19.0% | 16.2% |
| Cash conversion ratio | 1.63× | 2.01× | 1.68× |
| Capex coverage | 1.83× | 1.71× | 1.22× |
| Other reported items | |||
| Accumulated Other Comprehensive Income | -$659.0M | -$496.0M | — |
| Additional Paidin Capital | $910.0M | $1.04B | — |
| Adjusted Weighted Average Shares | 80.4M | 85.2M | 87.2M |
| Adjustments For Decrease Increase In Inventories | $28.0M | -$22.0M | -$243.0M |
| Adjustments For Decrease Increase In Trade and Other Receivables | $114.0M | -$213.0M | -$297.0M |
| Adjustments For Deferred Tax Expense | -$30.0M | -$109.0M | -$40.0M |
| Adjustments For Depreciation and Amortisation Expense | $387.0M | $378.0M | $363.0M |
| Adjustments For Gain Loss On Disposals Property Plant and Equipment | $4.0M | $0 | $80.0M |
| Adjustments For Income Tax Expense | $6.0M | $43.0M | $2.0M |
| Adjustments For Increase Decrease In Trade and Other Payables | -$95.0M | $426.0M | $596.0M |
| Adjustments For Undistributed Profits of Investments Accounted For Using Equity Method | $1.0M | $1.0M | $1.0M |
| Cash Flows From Used In Increase Decrease In Current Borrowings | -$126.0M | $61.0M | $167.0M |
| Comprehensive Income Attributable To Noncontrolling Interests | $1.0M | $1.0M | $0 |
| Comprehensive Income Attributable To Owners of Parent | $483.0M | $513.0M | $309.0M |
| Current Accrued Expenses and Other Current Liabilities | $1.06B | $1.14B | — |
| Current Prepaid Expenses | $167.0M | $173.0M | — |
| Current Tax Assets Current | $38.0M | $60.0M | — |
| Current Tax Liabilities Current | $120.0M | $122.0M | — |
| Dividends Paid Ordinary Shares Per Share | $2.74 | $2.66 | $2.58 |
| Dividends Paid To Equity Holders of Parent Classified As Financing Activities | $219.0M | $225.0M | $224.0M |
| Dividends Paid To Noncontrolling Interests Classified As Financing Activities | $5.0M | $1.0M | $2.0M |
| Dividends Recognised As Distributions To Noncontrolling Interests | $5.0M | $1.0M | $2.0M |
| Dividends Recognised As Distributions To Owners of Parent | $219.0M | $225.0M | $225.0M |
| Effect of Exchange Rate Changes On Cash and Cash Equivalents | $16.0M | -$20.0M | -$73.0M |
| Equity and Liabilities | $7.80B | $8.33B | — |
| Finance Income | $13.0M | $13.0M | $6.0M |
| Income Tax Relating To Components of Other Comprehensive Income That Will Be Reclassified To Profit Or Loss | -$1.0M | $1.0M | $9.0M |
| Increase Decrease In Cash and Cash Equivalents | -$168.0M | -$96.0M | -$375.0M |
| Increase Decrease Through Sharebased Payment Transactions | $13.0M | $11.0M | $10.0M |
| Interest Expense | $108.0M | $93.0M | $60.0M |
| Issued Capital | $80.0M | $88.0M | — |
| Number of Shares Authorised | 350.0M | 350.0M | — |
| Number of Shares Issued | 80.4M | 87.5M | — |
| Number of Shares Outstanding | 77.7M | 82.6M | — |
| Other Adjustments To Reconcile Profit Loss | $7.0M | -$10.0M | -$13.0M |
| Other Comprehensive Income | -$164.0M | $25.0M | -$116.0M |
| Other Comprehensive Income Before Tax | -$165.0M | $27.0M | -$107.0M |
| Other Comprehensive Income Before Tax Exchange Differences On Translation | -$161.0M | $20.0M | -$136.0M |
| Other Comprehensive Income Before Tax Gains Losses On Remeasurements of Defined Benefit Plans | -$4.0M | $7.0M | $29.0M |
| Other Comprehensive Income Net of Tax Gains Losses On Remeasurements of Defined Benefit Plans | -$3.0M | $6.0M | $20.0M |
| Other Current Assets | $34.0M | $33.0M | — |
| Other Current Liabilities | $231.0M | $223.0M | — |
| Other Finance Income Cost | -$16.0M | -$3.0M | -$5.0M |
| Other Noncurrent Assets | $548.0M | $606.0M | — |
| Other Noncurrent Liabilities | $92.0M | $109.0M | — |
| Other Operating Income Expense | -$19.0M | -$207.0M | $93.0M |
| Payments To Acquire Or Redeem Entitys Shares | $552.0M | $352.0M | $115.0M |
| Proceeds From Exercise of Options | $1.0M | $1.0M | $0 |
| Proceeds From Noncurrent Borrowings | $526.0M | $559.0M | $0 |
| Proceeds From Sales of Property Plant and Equipment Classified As Investing Activities | $17.0M | $4.0M | $101.0M |
| Purchase of Treasury Shares | $558.0M | $356.0M | $115.0M |
| Recognised Liabilities Defined Benefit Plan | $153.0M | $159.0M | — |
| Repayments of Noncurrent Borrowings | $306.0M | $533.0M | $357.0M |
| Research and Development Expense | $398.0M | $425.0M | $390.0M |
| Retained Earnings | $2.10B | $2.29B | — |
| Selling General and Administrative Expense | $530.0M | $500.0M | $440.0M |
| Share of Profit Loss of Associates and Joint Ventures Accounted For Using Equity Method | $7.0M | $5.0M | $3.0M |
| Shares In Entity Held By Entity Or By Its Subsidiaries Or Associates | 2.7M | 4.9M | — |
| Treasury Shares | $160.0M | $368.0M | — |
| Weighted Average Shares | 80.2M | 85.0M | 87.1M |
Methodology
Every line item above is a fact tagged in AUTOLIV, INC.'s annual report
filed in the European Single Electronic Format (ESEF) under the IFRS
taxonomy (ifrs-full) — the income statement, balance sheet
and cash-flow statement as the filer reported them. Values are shown
as-is, in the reporting currency (USD), without
rescaling; the row labels map to the underlying concept name (e.g.
Revenue → ifrs-full:Revenue, Operating profit →
ifrs-full:ProfitLossFromOperatingActivities, Diluted EPS →
ifrs-full:DilutedEarningsLossPerShare), and any concept
without a curated label is shown under “Other reported items” with its
de-camel-cased tag name. Only consolidated, default-member facts are
shown (segment / dimensional breakdowns are excluded).
“Derived metrics” (free cash flow, margins, ROE, …) are computed from those facts by the same model the U.S. financials pages use — not tagged by the filer.
Source: machine-readable OIM xBRL-JSON aggregated by filings.xbrl.org (XBRL International). Entity identity is resolved by LEI via the public-domain GLEIF register. This is reference data, not investment advice.